T cell epitopes are derived from the endogenous proteome and presented on the cell surface in the context of HLA. During the severe deregulation of malignant cells changes occur within the proteome, resulting in an altered epitope repertoire.
Immunotherapies of cancer depend on their ability to induce durable T cell mediated anti-tumor responses. It is therefore important to know which epitopes, or HLA ligands, are presented on the surface of the tumor cells.
We intend to probe T cell epitopes present on malignancies using HLA ligandome mass-spectrometry to assess and improve the current predictive algorithms.